Literature DB >> 15547022

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

H A W Neil1, V Seagroatt, D J Betteridge, M P Cooper, P N Durrington, J P Miller, M Seed, R P Naoumova, G R Thompson, R Huxley, S E Humphries.   

Abstract

OBJECTIVES: To assess the clinical and biochemical factors associated with inter-individual variation in susceptibility to coronary artery disease (CAD) in treated heterozygous familial hypercholesterolaemia.
DESIGN: A cross sectional study was conducted of 410 patients recruited from six lipid clinics in the UK.
RESULTS: CAD was documented in 104 of the 211 men and in 55 of the 199 women with mean ages of onset of 43.1 and 46.5 years, respectively. CAD was significantly more common in men (49% v 28%, p < 0.001) and in patients who had smoked cigarettes versus patients who had never smoked (51% v 28%, p < 0.001). After adjusting for age, sex, and current smoking status, there were no significant differences between patients with or without CAD in lipoprotein(a), homocysteine, fibrinogen, plasminogen activator inhibitor-1, white blood cell count, body mass index, glucose, triglyceride or total cholesterol. However, high density lipoprotein (HDL) cholesterol concentrations were significantly lower in those with CAD (6%, 95% confidence interval (CI) 1% to 11%, p = 0.03) and this difference was greater in women than men (12% v 2%, p = 0.041).
CONCLUSIONS: These results indicate that emerging coronary risk factors appear not to be associated with CAD in adults with treated familial hypercholesterolaemia, but the strong association with smoking suggests that patients should be identified early in childhood and discouraged from ever starting to smoke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547022      PMCID: PMC1768595          DOI: 10.1136/hrt.2003.022764

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  40 in total

1.  Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.

Authors:  H A Neil; T Hammond; R Huxley; D R Matthews; S E Humphries
Journal:  BMJ       Date:  2000-07-15

2.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

3.  Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.

Authors:  J T Real; F J Chaves; I Martínez-Usó; A B García-García; J F Ascaso; R Carmena
Journal:  Eur Heart J       Date:  2001-03       Impact factor: 29.983

4.  Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.

Authors:  P N Hopkins; S Stephenson; L L Wu; W A Riley; Y Xin; S C Hunt
Journal:  Am J Cardiol       Date:  2001-03-01       Impact factor: 2.778

5.  Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis.

Authors:  K E Heath; M Gahan; R A Whittall; S E Humphries
Journal:  Atherosclerosis       Date:  2001-01       Impact factor: 5.162

6.  Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia.

Authors:  C A Graham; E McClean; A J Ward; E D Beattie; S Martin; M O'Kane; I S Young; D P Nicholls
Journal:  Atherosclerosis       Date:  1999-12       Impact factor: 5.162

7.  Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.

Authors:  J Danesh; R Collins; R Peto
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

8.  Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia.

Authors:  D Bhatnagar; J Morgan; S Siddiq; M I Mackness; J P Miller; P N Durrington
Journal:  BMJ       Date:  2000-12-16

9.  Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.

Authors:  M A Umans-Eckenhausen; J C Defesche; E J Sijbrands; R L Scheerder; J J Kastelein
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

10.  Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.

Authors:  O Wiklund; B Angelin; S O Olofsson; M Eriksson; G Fager; L Berglund; G Bondjers
Journal:  Lancet       Date:  1990-06-09       Impact factor: 79.321

View more
  23 in total

1.  Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing.

Authors:  Steve E Humphries; Treena Cranston; Marcus Allen; Helen Middleton-Price; Maryam C Fernandez; Victoria Senior; Emma Hawe; Andrew Iversen; Richard Wray; Martin A Crook; Anthony S Wierzbicki
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

2.  Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease.

Authors:  Leonardo De Luca; Marcello Arca; Pier L Temporelli; Furio Colivicchi; Lucio Gonzini; Donata Lucci; Biagio Bosco; Mariella Callerame; Giulio V Lettica; Andrea Di Lenarda; Michele M Gulizia
Journal:  Clin Cardiol       Date:  2018-08-20       Impact factor: 2.882

3.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

4.  Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Authors:  Roeland Huijgen; Iris Kindt; Sjoerd B J Verhoeven; Eric J G Sijbrands; Maud N Vissers; John J P Kastelein; Barbara A Hutten
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

5.  Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia.

Authors:  Marta Futema; Vincent Plagnol; Ros A Whittall; H Andrew W Neil; Steve Eric Humphries
Journal:  J Med Genet       Date:  2012-10       Impact factor: 6.318

6.  Telomeres are shorter in myocardial infarction patients compared to healthy subjects: correlation with environmental risk factors.

Authors:  Cécilia G Maubaret; Klelia D Salpea; Anjly Jain; Jackie A Cooper; Anders Hamsten; Julie Sanders; Hugh Montgomery; Andrew Neil; Devaki Nair; Steve E Humphries
Journal:  J Mol Med (Berl)       Date:  2010-04-11       Impact factor: 4.599

7.  Association of a sequence variant in DAB2IP with coronary heart disease.

Authors:  Seamus C Harrison; Jackie A Cooper; Kawah Li; Phillipa J Talmud; Reecha Sofat; Jeffery W Stephens; Anders Hamsten; Julie Sanders; Hugh Montgomery; Andrew Neil; Steve E Humphries
Journal:  Eur Heart J       Date:  2011-03-28       Impact factor: 29.983

8.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.

Authors:  S E Humphries; R A Whittall; C S Hubbart; S Maplebeck; J A Cooper; A K Soutar; R Naoumova; G R Thompson; M Seed; P N Durrington; J P Miller; D J B Betteridge; H A W Neil
Journal:  J Med Genet       Date:  2006-12       Impact factor: 6.318

9.  Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population.

Authors:  Khalid K Alharbi; Mohammed A Aldahmesh; Emmanuel Spanakis; Lema Haddad; Roslyn A Whittall; Xiao-he Chen; Hamid Rassoulian; Matt J Smith; Julie Sillibourne; Nicola J Ball; Nikki J Graham; Patricia J Briggs; Iain A Simpson; David I W Phillips; Deborah A Lawlor; Shu Ye; Stephen E Humphries; Cyrus Cooper; George Davey Smith; Shah Ebrahim; Diana M Eccles; Ian N M Day
Journal:  Genome Res       Date:  2005-07       Impact factor: 9.043

10.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.

Authors:  Andrew Neil; Jackie Cooper; John Betteridge; Nigel Capps; Ian McDowell; Paul Durrington; Mary Seed; Steve E Humphries
Journal:  Eur Heart J       Date:  2008-10-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.